Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors

When treated with M701, patients with MA had significantly longer puncture intervals and a trend of extended survival time. The results were encouraging for patients with MA. A phase III clinical trial of M701 aimed at further validation is ongoing.

Authors

Institutions

Publication Details

Journal
Experimental Hematology and Oncology
Published
2025-11-22
DOI
https://doi.org/10.1186/s40164-025-00727-3
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors

Fang Su, Huiting Xu, Zhenghong Xiao, Yanhong Deng et al.
Experimental Hematology and Oncology
Monoclonal and Polyclonal Antibodies Research
article

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors

Fang Su, Huiting Xu, Zhenghong Xiao, Yanhong Deng, Rongbo Lin, Yu Kang, Rongrui Liu, Hanxiang An, Xiaojun Xiang, Wei Duan, Yuxian Bai, Shan Zeng, Qing Chen, Meili Sun, Ning Li, Tao Zhang, Yongqiang Li, Jun Zhao, Guiling Li, Ke Wang, Mingjun Zhang, XU Jian-ming, Jingdong Zhang, Qi Xu, Pengfei Zhou, Jing Zhang, Hongying Yang, Fei Yin, He Tian, Nong Xu, Weijie Zhang, Shaoyi Huang
article en

Abstract

When treated with M701, patients with MA had significantly longer puncture intervals and a trend of extended survival time. The results were encouraging for patients with MA. A phase III clinical trial of M701 aimed at further validation is ongoing.

Experimental Hematology and OncologyVol. 14(1)
Hebei Medical University (CN), Central South University (CN), Nanchang University (CN), Harbin Medical University (CN), Sun Yat-sen University (CN), Guangxi Medical University (CN), Shanxi Medical University (CN), Anhui Medical University (CN), Changzhi Medical College (CN), Kunming Medical University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Chinese PLA General Hospital (CN), First Affiliated Hospital of Xiamen University (CN), Sixth Affiliated Hospital of Sun Yat-sen University (CN), Sun Yat-sen Memorial Hospital (CN), Zhejiang Cancer Hospital (CN), Shandong Tumor Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), Fourth Hospital of Hebei Medical University (CN), Jinan Central Hospital (CN), Nanyang Institute of Technology (CN), First Affiliated Hospital of GuangXi Medical University (CN), Henan Cancer Hospital (CN), Obstetrics and Gynecology Hospital of Fudan University (CN), Fujian Provincial Cancer Hospital (CN), Second Affiliated Hospital of Anhui Medical University (CN), First Affiliated Hospital of Bengbu Medical College (CN), Wuhan YZY Biopharma (China) (CN), First Affiliated Hospital of Zhengzhou University (CN), Shanxi Academy of Medical Sciences (CN), Xiangya Hospital Central South University (CN), Hubei Cancer Hospital (CN), Liaoning Cancer Hospital & Institute (CN), Shandong First Medical University (CN), Union Hospital (CN), Beijing Obstetrics and Gynecology Hospital (CN), First Affiliated Hospital of Nanchang University (CN), First Affiliated Hospital Zhejiang University (CN)
Openalex Percentile: Top 49%
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.